About ArsenalBio
ArsenalBio is a company based in San Francisco (United States) founded in 2019 by Ken Drazan.. ArsenalBio has raised $631.16 million across 3 funding rounds from investors including Kleiner Perkins, T. Rowe Price and University of California. The company has 178 employees as of December 31, 2022. ArsenalBio offers products and services including AB-4000 Series. ArsenalBio operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Poseida Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 178 as on 31 Dec, 2022
- Founders Ken Drazan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Arsenal Biosciences, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$631.16 M (USD)
in 3 rounds
-
Latest Funding Round
$325.35 M (USD), Series C
Jul 09, 2024
-
Investors
Kleiner Perkins
& 22 more
-
Employee Count
178
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ArsenalBio
ArsenalBio offers a comprehensive portfolio of products and services, including AB-4000 Series. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Advanced T cell therapies designed to target and treat solid tumors effectively.
Unlock access to complete
Unlock access to complete
Funding Insights of ArsenalBio
ArsenalBio has successfully raised a total of $631.16M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $325.35 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $325.4M
-
First Round
First Round
(17 Oct 2019)
- Investors Count 23
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Series C - ArsenalBio | Valuation | Arch Venture Partners , Milky Way Investments Group | |
| Sep, 2022 | Amount | Series B - ArsenalBio | Valuation | Bristol-Myers Squibb , Westlake Village Biopartners | |
| Oct, 2019 | Amount | Series A - ArsenalBio | Valuation | Westlake Village Biopartners , Kleiner Perkins |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ArsenalBio
ArsenalBio has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, T. Rowe Price and University of California. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Venture capital is invested in biopharmaceutical and healthcare firms.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ArsenalBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ArsenalBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arsenalbio Comparisons
Competitors of ArsenalBio
ArsenalBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Poseida Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Arsenalbio
Frequently Asked Questions about ArsenalBio
When was ArsenalBio founded?
ArsenalBio was founded in 2019.
Where is ArsenalBio located?
ArsenalBio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of ArsenalBio?
Ken Drazan is the current CEO of ArsenalBio. They have also founded this company.
Is ArsenalBio a funded company?
ArsenalBio is a funded company, having raised a total of $631.16M across 3 funding rounds to date. The company's 1st funding round was a Series A of $85M, raised on Oct 17, 2019.
How many employees does ArsenalBio have?
As of Dec 31, 2022, the latest employee count at ArsenalBio is 178.
What does ArsenalBio do?
Developer of immune cell therapies. The company develops programmable immune cell therapies using cloud computing, genome engineering, and synthetic immunology technologies.
Who are the top competitors of ArsenalBio?
ArsenalBio's top competitors include Moderna, BeiGene and Juno Therapeutics.
What products or services does ArsenalBio offer?
ArsenalBio offers AB-4000 Series.
Who are ArsenalBio's investors?
ArsenalBio has 23 investors. Key investors include Kleiner Perkins, T. Rowe Price, University of California, Arch Venture Partners, and Bristol-Myers Squibb.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.